N	Concordance
1	y has been well established, but active immunotherapy of melanoma has been hampe
2	randomized controlled study of adjuvant immunotherapy combined with chemotherapy
3	>Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-t
4	s are necessary for prolonged antitumor immunotherapy. In addition, the data sug
5	e that low dose subcutaneous IL-2 based immunotherapy is feasible, relatively sa
6	 the important role of intravesical BCG immunotherapy and other immunotherapeuti
7	creasingly promising approach in cancer immunotherapy. The major goal is the act
8	his study indicates that combining gene immunotherapy approaches with radiothera
9	ects of active  specific intralymphatic immunotherapy with allogeneic pancreatic
10	  This study aimed to investigate local immunotherapy with Nocardia rubra cell w
11	 the design of adoptive T-cell-mediated immunotherapy trials for the treatment o
12	 to these findings this new local nasal immunotherapy with extract in powder for
13	ve stay and delay to resumption of oral immunotherapy are short. This approach h
14	nt women and children. Finally, passive immunotherapy with anti-HIV antibodies a
15	histamine tablets and allergen-specific immunotherapy on the seasonal changes in
16	atal systemic reactions to subcutaneous immunotherapy: a 10-year experience.    
17	nts were re-stung while receiving venom immunotherapy: only one had a mild syste